Log in to your Inderes Free account to see all free content on this page.

Zealand Pharma

538.5

DKK

-4.77 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-4.77%

-25.1%

-24.74%

-25.21%

-35.16%

-23.29%

+480.28%

+179.6%

+577.36%

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Market cap

38.26B DKK

Turnover

121.88M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

27.3.

2025

General meeting '25

8.5.

2025

Interim report Q1'25

14.8.

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Regulatory press release3/20/2025, 4:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Press release3/17/2025, 7:00 AM

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release3/12/2025, 6:00 AM

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

Regulatory press release2/20/2025, 12:00 PM

Zealand Pharma convenes its Annual General Meeting 2025

Regulatory press release2/20/2025, 9:08 AM

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Regulatory press release2/20/2025, 6:00 AM

Zealand Pharma Announces Financial Results for the Full Year 2024

Press release2/13/2025, 4:00 PM

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Press release1/7/2025, 4:00 PM

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Press release1/6/2025, 4:00 PM

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Regulatory press release12/25/2024, 4:40 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Regulatory press release12/25/2024, 4:30 PM

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Regulatory press release12/19/2024, 7:58 PM

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Press release12/10/2024, 2:00 PM

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press release11/13/2024, 5:00 PM

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Regulatory press release11/11/2024, 4:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Regulatory press release11/7/2024, 6:00 AM

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Regulatory press release10/8/2024, 10:45 PM

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Regulatory press release10/8/2024, 6:40 AM

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Regulatory press release9/30/2024, 3:00 PM

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.